Key Highlights

  • Karl Deisseroth, Peter Hegemann and Georg Nagel won the 2026 Nobel Prize in Physiology or Medicine for optogenetics.
  • Optogenetics uses light to control individual nerve cells in the brain; the prize sum is 12 million Swedish crowns.
  • Nagel and Hegemann showed in 2003 that channelrhodopsin-2 can generate electrical impulses with light in human cells.
  • The most advanced optogenetic therapies target autism spectrum disorder and retinitis pigmentosa, though both are still some way from patients.

A Prize for Switching Nerve Cells On and Off

American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel won the 2026 Nobel Prize in Physiology or Medicine on Monday for developing optogenetics, a technique that uses light to control individual nerve cells in the brain. The Nobel Assembly of Sweden's Karolinska Institutet said Deisseroth, 54, Hegemann, 71, and Nagel, 73, were selected for their discoveries concerning light-gated ion channels and optogenetics.

A member of the Nobel Committee said a new era in neuroscience has opened but that it is only the beginning, because researchers can now start to understand how the brain processes information and how different neurons interact.

The trio will share a prize sum of 12 million Swedish crowns (USD 1.2 million).

From Algae to Channelrhodopsin-2

Deisseroth was training to become a neurosurgeon when he met patients at a psychiatric clinic whom he could not help. That experience prompted a question: why does the brain work so differently in different people? The answer came from an unexpected place, an alga, and two German scientists.

Hegemann began investigating in the early 1990s how the alga Chlamydomonas reacts to light in half a millisecond. He hypothesized that a single protein both captured light and acted as an ion channel, and contacted Nagel to test it. Nagel injected Chlamydomonas genes into frog eggs and discovered channelrhodopsin-2, a light-sensitive ion channel.

In 2003, Nagel and Hegemann published findings showing the protein could be introduced into human cells to generate electrical impulses using light. Deisseroth showed the technique in rat nerve cells in 2005, and the method was named optogenetics in 2006.

The Laureates React

Deisseroth said he was still awake when the call came from Stockholm, calling himself a night owl. Hegemann said he was overwhelmed to receive a call from a number he recognized as Swedish. Nagel said he was sitting on a terrace in a village outside Naples when the call came through, and that he had thought it would not happen.

Treatments Under Development

Researchers are using the laureates' work to gain insights into brain disorders. Animal models are being used to study schizophrenia, Alzheimer's disease, Parkinson's disease, epilepsy and addiction, conditions that affect millions of people worldwide and have limited treatment options. Deisseroth used optogenetics to control the movements of mouse whiskers by activating specific nerve cells in the motor cortex, and used light to wake sleeping mice.

Researchers are also applying the technique to try to restore vision to people blinded by retinitis pigmentosa, a progressive eye disease, by inserting a light-sensitive protein into the retina. They are exploring cochlear implants as well, aiming for more precise stimulation of the auditory nerve than current electrical devices.

The most advanced treatments are an autism spectrum disorder therapy from a US-based biotech company co-founded by Deisseroth and a vision restoration medicine for retinitis pigmentosa from another US company. Both are still some way from reaching patients.

A researcher at a Barcelona hospital said that in laboratory animals, scientists have controlled emotions, created false memories and recovered lost memories in Alzheimer's models. He said the promise optogenetics has yet to fulfil is treating diseases of the human brain.

Where Things Stand

The prize may draw renewed attention to optogenetics-based therapies as they continue moving through development toward potential patient use. Researchers and investors in the space may watch for further clinical progress on the most advanced programs targeting autism spectrum disorder and retinitis pigmentosa.